Murphy Middleton Hinkle & Parker’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.5M | Hold |
3,750
| – | – | 1.83% | 15 |
|
|
2026
Q1 | $3.45M | Buy |
+3,750
| New | +$3.8M | 1.6% | 17 |
|
|
2025
Q4 | – | Sell |
-3,886
| Closed | -$2.97M | – | 189 |
|
|
2025
Q3 | $2.97M | Sell |
3,886
-44
| -1% | -$32.7K | 1.45% | 17 |
|
|
2025
Q2 | $3.25M | Hold |
3,930
| – | – | 1.82% | 15 |
|
|
2025
Q1 | $3.25M | Buy |
3,930
+51
| +1% | +$42.4K | 1.82% | 15 |
|
|
2024
Q4 | $2.99M | Sell |
3,879
-270
| -7% | -$224K | 1.69% | 15 |
|
|
2024
Q3 | $3.68M | Sell |
4,149
-123
| -3% | -$111K | 1.98% | 16 |
|
|
2024
Q2 | $3.87M | Sell |
4,272
-28
| -0.7% | -$22.4K | 2.25% | 11 |
|
|
2024
Q1 | $3.35M | Sell |
4,300
-40
| -0.9% | -$28.5K | 1.95% | 13 |
|
|
2023
Q4 | $2.53M | Buy |
4,340
+143
| +3% | +$83.5K | 1.56% | 19 |
|
|
2023
Q3 | $2.25M | Buy |
4,197
+11
| +0.3% | +$5.67K | 1.45% | 21 |
|
|
2023
Q2 | $1.96M | Buy |
4,186
+1
| +0% | +$419 | 1.23% | 27 |
|
|
2023
Q1 | $1.44M | Buy |
4,185
+1
| +0% | +$337 | 0.89% | 38 |
|
|
2022
Q4 | $1.53M | Buy |
4,184
+1
| +0% | +$355 | 0.96% | 34 |
|
|
2022
Q3 | $1.35M | Sell |
4,183
-18
| -0.4% | -$5.7K | 0.94% | 36 |
|
|
2022
Q2 | $1.36M | Buy |
4,201
+185
| +5% | +$55.5K | 0.88% | 39 |
|
|
2022
Q1 | $1.15M | Buy |
4,016
+948
| +31% | +$244K | 0.62% | 49 |
|
|
2021
Q4 | $847K | Sell |
3,068
-58
| -2% | -$14.7K | 0.45% | 72 |
|
|
2021
Q3 | $722K | Sell |
3,126
-12
| -0.4% | -$2.96K | 0.42% | 76 |
|
|
2021
Q2 | $720K | Sell |
3,138
-14
| -0.4% | -$2.81K | 0.4% | 76 |
|
|
2021
Q1 | $589K | Sell |
3,152
-82
| -3% | -$16K | 0.34% | 84 |
|
|
2020
Q4 | $546K | Sell |
3,234
-114
| -3% | -$17K | 0.36% | 80 |
|
|
2020
Q3 | $496K | Sell |
3,348
-658
| -16% | -$102K | 0.36% | 82 |
|
|
2020
Q2 | $658K | Buy |
4,006
+2
| +0% | +$307 | 0.49% | 65 |
|
|
2020
Q1 | $555K | Buy |
4,004
+2
| +0% | +$275 | 0.49% | 68 |
|
|
2019
Q4 | $526K | Buy |
4,002
+22
| +0.6% | +$2.55K | 0.35% | 79 |
|
|
2019
Q3 | $445K | Buy |
3,980
+3
| +0.1% | +$334 | 0.32% | 82 |
|
|
2019
Q2 | $441K | Buy |
3,977
+2
| +0.1% | +$236 | 0.31% | 81 |
|
|
2019
Q1 | $516K | Buy |
3,975
+2
| +0.1% | +$243 | 0.35% | 75 |
|
|
2018
Q4 | $460K | Sell |
3,973
-110
| -3% | -$12.3K | 0.35% | 75 |
|
|
2018
Q3 | $438K | Buy |
4,083
+2
| +0% | +$200 | 0.31% | 84 |
|
|
2018
Q2 | $348K | Buy |
4,081
+2
| +0% | +$164 | 0.26% | 94 |
|
|
2018
Q1 | $316K | Buy |
4,079
+2
| +0% | +$161 | 0.25% | 97 |
|
|
2017
Q4 | $344K | Buy |
+4,077
| New | +$347K | 0.26% | 95 |
|
Other funds holding LLY
SC
ONB
GIM
WAM
CRM
VNIM
Murphy Middleton Hinkle & Parker's LLY Position: Q2 2026 in Review
Murphy Middleton Hinkle & Parker held its Eli Lilly (LLY) position steady in Q2 2026 at 3,750 shares worth $4.5M. The position accounts for 1.83% of the portfolio, ranked #15.
Murphy Middleton Hinkle & Parker first reported a position in LLY in Q4 2017 and has held it in 34 quarters since. 923 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Murphy Middleton Hinkle & Parker held 3,750 shares of Eli Lilly worth $4.5M as of Q2 2026.
- Murphy Middleton Hinkle & Parker left its Eli Lilly share count unchanged in Q2 2026.
- Eli Lilly made up 1.83% of Murphy Middleton Hinkle & Parker's portfolio in Q2 2026, its #15 holding.
- Murphy Middleton Hinkle & Parker first reported a position in Eli Lilly in Q4 2017 and has held it in 34 quarters since.
- 923 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Murphy Middleton Hinkle & Parker's 13F filing for Q2 2026, filed 14 Jul 2026.